KIN Stock Analysis: Kinepolis | BR

Entertainment | BR, Belgium | Market Cap: 1.288m EUR | 12M Return: 49.9% | BE0974274061 | Charts, Fundamentals & Technical Analysis

Cinema Operations, Concessions, Advertising, Film Distribution
Total Rating 58
Safety 64
Buy Signal 1.83
Entertainment
Industry Rotation: -3.5
Market Cap: 1.50B
Avg Turnover: 2.34M
Risk 3d forecast
Volatility26.0%
VaR 5th Pctl4.09%
VaR vs Median-4.47%
Reward TTM
Sharpe Ratio1.63
Rel. Str. IBD95.4
Rel. Str. Peer Group95.3
Character TTM
Beta0.195
Beta Downside-0.083
Hurst Exponent0.537
Drawdowns 3y
Max DD47.91%
CAGR/Max DD0.06
CAGR/Mean DD0.12

Warnings

Altman Z'' In Financial Distress Zone

Tailwinds

Supp Ema8
Rs Leader
Idiosyncratic Leader
Confidence
Tailwind

Seasonality

Not enough history
Description: KIN Kinepolis

Kinepolis Group NV is a Belgian-headquartered cinema operator that runs multiplex complexes across Belgium, Canada, France, the Netherlands, the United States, Spain, Luxembourg, and Switzerland. The group operates under several regional and national brands, including KINEPOLIS, Landmark Cinemas, MJR THEATRES, and Emagine Entertainment, giving it a diversified geographic footprint in the European and North American exhibition markets.

Beyond ticket sales, the company pursues a multi-revenue model typical of large cinema chains: in-theatre concessions (beverages, snacks, and non-food items), in-theatre advertising, film distribution, private screenings, and corporate events and conferences. It also offers media channels that allow third-party businesses to reach cinema audiences, extending its monetization beyond traditional box office income. The company was incorporated in 1976 and is headquartered in Brussels, Belgium.

Headlines to Watch Out For
  • Box office recovery drives ticket and concession revenue growth
  • US expansion through MJR and Emagine acquisitions boosts market presence
  • Streaming competition pressures cinema attendance and advertising revenue
Piotroski VR-10 (Strict) 4.5
Net Income: 56.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA -2.25 > 1.0
NWC/Revenue: -24.92% < 20% (prev -21.70%; Δ -3.21% < -1%)
CFO/TA 0.13 > 3% & CFO 177.8m > Net Income 56.2m
Net Debt (1.11b) to EBITDA (189.6m): 5.88 < 3
Current Ratio: 0.61 > 1.5 & < 3
Outstanding Shares: last quarter (26.7m) vs 12m ago -0.11% < -2%
Gross Margin: 25.93% > 18% (prev 24.54%; Δ 1.39% > 0.5%)
Asset Turnover: 52.82% > 50% (prev 56.91%; Δ -4.09% > 0%)
Interest Coverage Ratio: 2.73 > 6 (EBIT TTM 106.1m / Interest Expense TTM 38.8m)
Altman Z'' 0.64
A: -0.11 (Total Current Assets 248.7m - Total Current Liabilities 410.4m) / Total Assets 1.41b
B: 0.18 (Retained Earnings 256.0m / Total Assets 1.41b)
C: 0.09 (EBIT TTM 106.1m / Avg Total Assets 1.23b)
D: 0.21 (Book Value of Equity 243.6m / Total Liabilities 1.17b)
Altman-Z'' = 0.64 = B
Beneish M -2.95
DSRI: 1.04 (Receivables 42.6m/37.6m, Revenue 648.8m/593.3m)
GMI: 0.95 (GM 24.54% / 25.93%)
AQI: 1.06 (AQ_t 0.22 / AQ_t-1 0.21)
SGI: 1.09 (Revenue 648.8m / 593.3m)
TATA: -0.09 (NI 56.2m - CFO 177.8m) / TA 1.41b)
Beneish M = -2.95 (Cap -4..+1) = A
What is the price of KIN shares?

As of September 11, 2026, the stock is trading at EUR 48.60 with a total of 31,413 shares traded. Over the past week, the price has changed by +0.93%, over one month by +18.39%, over three months by +47.95% and over the past year by +49.88%.

Current recommended Stop Loss: 47.30 (which is 2.7% or 1.2 ATR below the current price).

Is KIN a buy, sell or hold?

Kinepolis has no consensus analysts rating.

Kinepolis (KIN) - Fundamental Data Overview as of 05 September 2026
Market Cap USD = 1.50b (1.29b EUR * 1.163 EUR.USD)
P/E Trailing = 21.2115
P/E Forward = 20.3252
P/S = 1.9355
P/B = 5.2213
P/EG = 5.2337
Revenue TTM = 648.8m EUR
EBIT TTM = 106.1m EUR
EBITDA TTM = 189.6m EUR
Long Term Debt = 211.1m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 269.9m EUR (from shortTermDebt, last quarter)
Debt = 1.31b EUR (from shortLongTermDebtTotal, last quarter) + Leases 307.9m
Net Debt = 1.11b EUR (calculated: Debt 1.31b - CCE 194.8m)
Enterprise Value = 2.40b EUR (1.29b + Debt 1.31b - CCE 194.8m)
Interest Coverage Ratio = 2.73 (Ebit TTM 106.1m / Interest Expense TTM 38.8m)
EV/FCF = 18.00x (Enterprise Value 2.40b / FCF TTM 133.5m)
FCF Yield = 5.56% (FCF TTM 133.5m / Enterprise Value 2.40b)
FCF Margin = 20.57% (FCF TTM 133.5m / Revenue TTM 648.8m)
Net Margin = 8.66% (Net Income TTM 56.2m / Revenue TTM 648.8m)
Gross Margin = 25.93% ((Revenue TTM 648.8m - Cost of Revenue TTM 480.6m) / Revenue TTM)
Gross Margin QoQ = 24.96% (prev 27.01%)
Tobins Q-Ratio = 1.70 (Enterprise Value 2.40b / Total Assets 1.41b)
Interest Expense / Debt = 2.97% (Interest Expense 38.8m / Debt 1.31b)
Taxrate = 24.69% (18.4m / 74.6m)
NOPAT = 79.9m (EBIT 106.1m * (1 - 24.69%))
Current Ratio = 0.61 (Total Current Assets 248.7m / Total Current Liabilities 410.4m)
Debt / Equity = 5.38 (Debt 1.31b / totalStockholderEquity, last quarter 243.6m)
Debt / EBITDA = 5.88 (Net Debt 1.11b / EBITDA 189.6m)
Debt / FCF = 8.35 (Net Debt 1.11b / FCF TTM 133.5m)
Total Stockholder Equity = 225.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.58% (Net Income 56.2m / Total Assets 1.41b)
RoE = 24.94% (Net Income TTM 56.2m / Total Stockholder Equity 225.4m)
RoCE = 24.32% (EBIT 106.1m / Capital Employed (Equity 225.4m + L.T.Debt 211.1m))
RoIC = 6.44% (NOPAT 79.9m / Invested Capital 1.24b)
WACC = 4.43% (E(1.29b)/V(2.60b) * Re(6.67%) + D(1.31b)/V(2.60b) * Rd(2.97%) * (1-Tc(0.25)))
Discount Rate = 6.67% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -11.80 | Cagr: -0.32%
[DCF] Terminal Value 76.61% ; FCFF base≈128.8m ; Y1≈139.6m ; Y5≈172.2m
[DCF] Fair Price = 56.91 (EV 2.64b - Net Debt 1.11b = Equity 1.52b / Shares 26.7m; r=8.35% [WACC [floored]]; 5y FCF grow 9.57% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 38.30 | Revenue CAGR: 2.21% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=2.53 | Chg30d=+8.64% | Revisions=+25% | GrowthEPS=+64.5% | GrowthRev=+33.9%
EPS next Year (2027-12-31): EPS=2.91 | Chg30d=+6.01% | Revisions=+25% | GrowthEPS=+14.9% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: +40% (up=2, down=0)